Some studies report an inverse correlation between IBD activity and serum DPP-4 levels, while others suggest that long-term DPP-4 inhibitor use in patients with type 2 diabetes may increase IBD risk [105,106]. This evidence concerns the gene DPP4 and irritable bowel syndrome.